Climacteric · Nov 17, 2026

Dry eye disease in the menopausal transition: toward recognition as a hormonal manifestation

By Skurski ZP, Mikkilineni A, Simon JA

Dry eye symptoms affect an estimated 64-80% of perimenopausal and postmenopausal women, placing dry eye disease (DED) among the most prevalent yet least recognized manifestations of the menopausal endocrine transition. The pathophysiology centers on androgen deficiency and altered estrogen signaling, with sex hormone receptors expressed throughout the ocular surface, and the 2025 Tear Film and Ocular Surface Society Dry Eye Workshop III recognizes sex, gender and hormones as one of seven major domains influencing DED. Objective ocular surface signs are significantly worse in postmenopausal compared with premenopausal women even when subjective symptoms are similar, mirroring the symptom-sign dissociation well recognized in genitourinary syndrome of menopause. This hormonally mediated dry eye is described in recent literature as menopausal dry eye. This opinion advocates for routine screening using the validated Ocular Surface Disease Index-6 questionnaire, counseling patients on the ocular implications of hormone therapy and timely referral to eye care providers for persistent or moderate-to-severe symptoms. Recognizing dry eye as a menopausal disease can improve how ocular symptoms are attributed, discussed and treated in midlife women.

doi.org/10.1080/13697137.2026.2752791PubMed 43042500Mechanisms

AgingResearch.News